Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Written by GetSignal with AI from each earnings call; every brief quotes the executives' own words. Key facts are what the company said on the call, not our forecast. Not investment advice.
Each firm's latest price target on GILD, newest first
Firm
Rating
Target
Action
Date
Argus
Not stated
$190
Target set
Jefferies
Buy
$196
Target set
Bernstein
Outperform
$175
Raised from $160
UBS
Buy
$195
Raised from $175
TD Cowen
Buy
$175
Target set
BMO Capital
Outperform
$184
Raised from $160
BofA Securities
Buy
$164
Raised from $162
RBC Capital
Sector Perform
$126
Raised from $123
Truist Securities
Buy
$158
Raised from $150
HSBC
Buy
$175
Raised from $155
Barclays
Equal Weight
$145
Cut from $155
Morgan Stanley
Overweight
$165
Cut from $166
Leerink
Market Perform
$127
Target set
Maxim Group
Buy
$165
Target set
Mizuho
Not stated
$170
Raised from $140
Scotiabank
Sector Outperform
$177
Target set
Oppenheimer
Not stated
$165
Target set
Cantor Fitzgerald
Overweight
$155
Raised from $135
Needham
Buy
$170
Target set
Baird
Not stated
$145
Target set
Wells Fargo
Overweight
$165
Target set
Wolfe Research
Not stated
$150
Target set
Each firm's latest target from the past year, with the rating stated with its note. These are the firms' own views, not GetSignal's, and we do not endorse them. Not investment advice.
2 other firms rated GILD in the past year with no current target listed here. Ratings and targets come from licensed market data providers. A target is listed only after its firm and company are confirmed against a report of the note. As of Nov 13, 2026.
Proxy statementas filed for fiscal 2025 · proxy filed Mar 20, 2026
Executive pay
Daniel P. O’Day’s pay as CEO came to $28.4M for fiscal 2025.
Executive
Salary
Stock awards
Other
Total
Daniel P. O’DayChairman and Chief Executive Officer
$1.8M
$15.2M
$11.4M
$28.4M
Dietmar Berger, M.D., Ph.D.Chief Medical Officer
$969K
$7.0M
$6.0M
$13.9M
Johanna MercierChief Commercial and Corporate Affairs Officer
$1.2M
$4.6M
$3.6M
$9.3M
Andrew D. DickinsonChief Financial Officer
$1.1M
$4.3M
$3.3M
$8.8M
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. 1 executive who has since left the company is named in that filing and not shown here. Read the filing
13F filings13F positions as of Jun 30, 2026
Institutional holders
2,293 institutions reported Gilead Sciences shares in 13F filings for Jun 30, 2026.
Holder
Value
Shares
Shares vs prior qtr
% of shares out
BlackRock, Inc.
$15.4B
121,844,108
+2.4%
9.80%
Vanguard Capital Management LLC
$10.2B
81,091,734
+0.5%
6.52%
FMR LLC
$8.4B
66,870,816
-7.0%
5.38%
State Street Corp
$7.7B
61,216,552
+2.3%
4.93%
Capital World Investors
$5.2B
40,988,975
-0.7%
3.30%
Invesco Ltd.
$5.0B
39,819,151
+52.8%
3.20%
Vanguard Portfolio Management LLC
$4.5B
35,316,168
+0.5%
2.84%
Geode Capital Management, LLC
$3.8B
30,065,642
+1.1%
2.42%
T. Rowe Price Associates, Inc.
$3.8B
29,996,694
+14.3%
2.41%
Morgan Stanley
$3.0B
24,004,354
+3.0%
1.93%
Dodge & Cox
$3.0B
23,677,567
-2.4%
1.90%
Norges Bank
$2.8B
21,965,555
New
1.77%
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. New: not in this holder's prior 13F as reported; a change of filer ID can also show as new. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
2 of the 97 fund managers we track list GILD shares among the largest positions in their latest 13F. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.
One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.
Other Form 4 activity (20)
Insider
Event
Shares
Date
Daniel Patrick O'DayChairman & CEO
Option exercise
9,810
Nov 5, 2026
Daniel Patrick O'DayChairman & CEO
Option exercise
102,619
Nov 4, 2026
Daniel Patrick O'DayChairman & CEO
Option exercise
15,881
Oct 30, 2026
Erin BurkhartSVP, Controllership
Tax withholding
768
Sep 22, 2026
Erin BurkhartSVP, Controllership
Option exercise
2,223
Sep 22, 2026
Daniel Patrick O'DayChairman & CEO
Tax withholding
4,230
Sep 10, 2026
Daniel Patrick O'DayChairman & CEO
Option exercise
8,780
Sep 10, 2026
Keeley M. Cain WettanEVP Gen Counsel, Legal & Comp
Tax withholding
285
Sep 10, 2026
Keeley M. Cain WettanEVP Gen Counsel, Legal & Comp
Option exercise
590
Sep 10, 2026
Johanna MercierChief Comm & Corp Aff Officer
Tax withholding
1,347
Sep 10, 2026
Johanna MercierChief Comm & Corp Aff Officer
Option exercise
2,797
Sep 10, 2026
Dietmar BergerChief Medical Officer
Tax withholding
263
Sep 10, 2026
Dietmar BergerChief Medical Officer
Option exercise
533
Sep 10, 2026
Andrew D. DickinsonChief Financial Officer
Tax withholding
1,347
Sep 10, 2026
Andrew D. DickinsonChief Financial Officer
Option exercise
2,797
Sep 10, 2026
Anthony WeltersDirector
Option exercise
18,000
Aug 26, 2026
Jeffrey BluestoneDirector
Option exercise
9,665
Aug 20, 2026
Johanna MercierChief Comm & Corp Aff Officer
Option exercise
25,000
Aug 17, 2026
Keeley M. Cain WettanEVP Gen Counsel, Legal & Comp
Tax withholding
2,908
Aug 10, 2026
Keeley M. Cain WettanEVP Gen Counsel, Legal & Comp
Option exercise
6,002
Aug 10, 2026
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
STOCK Act20 disclosures of 113 on record · median 28d of the 45 allowed
Congress trades in GILD
Since the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.
+43.0%since the tradeEstimated entry price $117.41, close on Fri Mar 7, 2025Current price $167.95, close on Thu Nov 12
Mar 7, 2025
Apr 10, 2025
34d
Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it. On an option line the prices are the stock's, never the option's: the premium is never disclosed.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no prices or move are shown for that row.
A further member reports a position estimated under $1,000; that member is not listed.
The largest estimated position is in the $100,001 - $250,000 band. Estimate, as of Nov 12, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, marked to the latest close we hold. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
On Form 4, code P is an open-market purchase and S an open-market sale; a sale marked scheduled was set up in advance under a Rule 10b5-1 plan. Awards, option exercises, tax withholding and gifts (A, M, F and G) are listed under Other Form 4 activity and never counted as either.
A STOCK Act disclosure gives each trade as a band of dollar values, which we do not narrow, and is due within 45 days of the trade. An option is described by its underlying company's name; its row says it is an option.
What the filings on GILD show and how current they are.
Are insiders buying or selling GILD?
Across the 20 most recent open-market filings shown here, 0 were purchases and 20 were sales. 20 were scheduled in advance under a Rule 10b5-1 plan.
Which members of Congress have traded GILD?
Ro Khanna, Alan Armstrong, Jared Moskowitz, Josh Gottheimer, Val T. Hoyle, Jefferson Shreve and others disclosed GILD transactions in the filings shown here.
Which members of Congress hold GILD?
15 members of Congress report a position of $1,000 or more in GILD in the estimate we hold as of Nov 12, 2026. The two largest estimated positions belong to J. French Hill and Jacky Rosen; Deborah K. Ross holds one of the next largest, in the $15,001 - $50,000 band. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
Is GILD in the S&P 500 or the Nasdaq 100?
Gilead Sciences, Inc. is a current member of the S&P 500 and Nasdaq 100, per the membership list we hold as of Nov 13, 2026. Current members of either index get a page here whatever their filing history.
How quickly are GILD trades disclosed?
Insider filings on this page reached the public a median of 1 business day after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 28 days, against the 45 the STOCK Act allows.